Hello, Bonjour, Olá:

My name is Nikolaj Gilbert. It was my honor to join PATH as president and CEO in January 2020. I offer my heartfelt thanks to David and the board for placing their faith in me, to Steve and everyone at PATH for their outstanding contributions to global public health, and to all of you—our donors and partners—for making those contributions possible.

When I first learned about PATH, I was so impressed by its people—their focus on health equity, the scale of their impact, and the breadth and depth of their expertise. Now, after my first six months, my admiration has only grown.

In countries and communities around the world, PATH and our partners are working together to curb COVID-19's awful impact and maintain a whole host of essential efforts—strengthening national and global health systems; controlling and eliminating infectious diseases like HIV, tuberculosis, and malaria; advancing childhood immunization; and more. Of course, no one who knows PATH is surprised by this. For more than 40 years, this organization has been growing and changing to meet the needs of the people it serves. This is precisely why I wanted to join PATH. As the world faces increasingly complex challenges, we will need increasingly integrated solutions. PATH possesses the end-to-end expertise, cross-sector experience, and global reach required to develop such solutions. In the years ahead, we will become even more equitable, holistic, and agile. We will ready PATH—and ready the world—for the challenges of tomorrow, even as we respond to the challenges of today.

Thank you again to the board, to PATH’s dedicated staff, and to all of you, our many partners and donors. Though we face new challenges, we rise together to meet them as one global team.

Thank you, Merci, Obrigado,

Nikolaj Gilbert

From PATH’s board chair and new president

Friends, supporters, colleagues:

On behalf of the board and our entire global team, thank you for your support of PATH in 2019. Because of partners and donors like you, it was another momentous year for our organization and for the pursuit of health equity.

During 2019, PATH expanded access to essential medicines, accelerated the development of new vaccines, and launched a Center of Digital and Data Excellence. We successfully commercialized new medical devices and rapid diagnostics that meet the needs of low-resource settings. And we supported country partners around the world as they advanced equitable health policies, strengthened health systems, and established emergency operations centers.

Last year also saw profound change for PATH, as Steve Davis retired as our president and CEO. Steve was an extraordinary and inspirational leader. During his tenure, he led significant growth in PATH’s reach and impact; united our efforts under a single, globally recognized brand; and firmly established PATH as a global voice for health equity. He leaves a weighty legacy and we are grateful for all of his outstanding work.

As Steve departed, we were privileged to secure Nikolaj Gilbert—former global partnerships director for the United Nations Office for Project Services—as our new president and CEO. We are inspired by Nikolaj’s vision for the future of global health and development, his extensive cross-sector experience, and his values-driven approach to leadership. We are thrilled to have him on board.

Together, under Nikolaj’s leadership, we will continue to advance PATH’s mission and improve public health around the world. Once again, on behalf of the board and everyone at PATH, thank you for your continued support and for sharing the journey.

With gratitude,

David King

Chair, Board of Directors

Hello, Bonjour, Olá:

My name is Nikolaj Gilbert. It was my honor to join PATH as president and CEO in January 2020. I offer my heartfelt thanks to David and the board for placing their faith in me, to Steve and everyone at PATH for their outstanding contributions to global public health, and to all of you—our donors and partners—for making those contributions possible.

When I first learned about PATH, I was so impressed by its people—their focus on health equity, the scale of their impact, and the breadth and depth of their expertise. Now, after my first six months, my admiration has only grown.

In countries and communities around the world, PATH and our partners are working together to curb COVID-19’s awful impact and maintain a whole host of essential efforts—strengthening national and global health systems; controlling and eliminating infectious diseases like HIV, tuberculosis, and malaria; advancing childhood immunization; and more. Of course, no one who knows PATH is surprised by this. For more than 40 years, this organization has been growing and changing to meet the needs of the people it serves.

This is precisely why I wanted to join PATH. As the world faces increasingly complex challenges, we will need increasingly integrated solutions. PATH possesses the end-to-end expertise, cross-sector experience, and global reach required to develop such solutions. In the years ahead, we will become even more equitable, holistic, and agile. We will ready PATH—and ready the world—for the challenges of tomorrow, even as we respond to the challenges of today.

Thank you again to the board, to PATH’s dedicated staff, and to all of you, our many partners and donors. Though we face new challenges, we rise together to meet them as one global team.

Thank you, Merci, Obrigado,
“Together, we are strengthening the country’s health system, so that one day, PATH won’t be needed.”

GUY BOKONGO
Country Lead
Advocacy and Public Policy
Democratic Republic of the Congo

Guy co-organized his country’s largest-ever National Forum on Immunization and Polio Eradication in 2019. The summit led to President Tshisekedi’s powerful and public commitment to immunization as a pillar of universal health coverage.

PATH accelerated global progress toward health equity in 2019 with new vaccines, faster data systems, affordable devices, equitable policies, and so much more. These are just a few examples that demonstrate the breadth and depth of our impact.

Preventing, detecting, and responding to outbreaks
PATH led the implementation of the US Centers for Disease Control and Prevention’s Global Health Security Project in the Democratic Republic of the Congo (DRC), India, Senegal, Tanzania, and Vietnam, enhancing the ability of each country’s health system to prevent, detect, and respond to infectious disease outbreaks. We also designed a mobile emergency operations center—now dedicated to COVID-19—to support ongoing outbreak response in the DRC and served as a lead partner under the US Agency for International Development’s (USAID’s) Infectious Disease Detection and Surveillance program—hosting the project in Senegal, Tanzania, Uganda, and Vietnam, and supporting implementation in several other countries.

Developing and introducing vaccines for all
PATH achieved a host of vaccine milestones in 2019. We helped PNEUMOSIL®—a $2-per-dose pneumococcal conjugate vaccine—receive World Health Organization prequalification, a critical step in removing the barrier of affordability for countries around the world; supported Pakistan’s introduction of a new typhoid conjugate vaccine reaching nearly 10 million children; began a pivotal Phase 3 clinical study of a polyvalent meningococcal conjugate vaccine capable of targeting all disease-causing meningococcal serogroups in Africa, as well as a Phase 3 efficacy trial of a new non-replicating rotavirus vaccine candidate. PATH’s Center for Vaccine Innovation and Access works on dozens of projects targeting 20 diseases, including Tanzania, used weather data to help predict and respond to malaria outbreaks, helped the DRC establish its first-ever digital health agency, and continued to support the World Health Organization as it develops and implements its global digital health strategy.

Leading the digital transformation
In 2019, PATH continued driving global digital health transformation. We launched our Center of Digital and Data Excellence, scaled up electronic immunization registries across 50 percent of
A laboratory technician performs a fluorescent spot test for glucose-6-phosphate dehydrogenase (G6PD) deficiency. After supporting the development of the STANDARD™ G6PD diagnostic, PATH’s diagnostics and market dynamics teams are paving the way for its introduction.

We are passionate about transforming health services, so they reflect what people want and need, including self and community-based care options.”

KIMBERLY GREEN, PhD
Program Leader
HIV and Tuberculosis
Vietnam

Kim and her team helped to design, implement, and scale up differentiated partner notification services in the Democratic Republic of the Congo, Kenya, Ukraine, and Vietnam. In each of these countries, people newly diagnosed with HIV are now offered a suite of options for disclosing their positive status and providing HIV testing services to their partners and families.
Reimagining primary health care
PATH and the Bill & Melinda Gates Foundation launched the Living Labs initiative in Kenya—a human-centered approach to health care innovation where health care workers and PATH designers and researchers work side-by-side to define challenges and develop solutions. Their focus in 2019? Increasing immunization coverage across sub-Saharan Africa.

Creating innovative devices and diagnostics
PATH and our partners advanced a host of new devices and diagnostics aimed at improving public health. Notable milestones included earning European (CE mark) approval for the Ellavi Uterine Balloon Tamponade—an affordable, lifesaving device used to treat postpartum hemorrhage—and receiving World Health Organization prequalification for the first solar-powered vaccine refrigerators in Senegal and first PATH-derived freeze prevention vaccine carriers in Nepal. We also partnered with the University of Washington to develop a bag-mediated filtration system that captures viruses from sewage—allowing researchers to monitor for polio and other viruses.

Maximizing impact through policy
PATH’s advocacy team helped advance global progress toward health equity, directly contributing to the adoption of 33 policies, the enactment of 21 budgets, and the implementation of 23 policies in the DRC, Europe, Kenya, South Africa, Uganda, and the United States. Key policy wins included the passage of Kenya’s health research & development policy and an unprecedented commitment to childhood immunization from the president of the DRC. His commitment followed a PATH-coordinated, largest-ever national forum on immunization and polio eradication.

Advancing essential medicines
An estimated 64 percent of deaths from diarrhea among children under age five—nearly 320,000 each year—could be prevented with full coverage of oral rehydration solution (ORS) and zinc, along with other community interventions. PATH played an instrumental role in the World Health Organization’s (WHO’s) 2019 decision to update its Model List of Essential Medicines (EML) and Model List of Essential Medicines for Children to include co-packaged ORS and zinc as medicine for pediatric diarrhea management—petitioning the WHO EML Secretariat, securing letters of support, and conducting a global advocacy campaign.

Feeding the future
In India, PATH supported the establishment of 16 lactation management centers in seven states and worked with the Department of Food and Public Distribution to develop a centralized supply scheme that will supply fortified rice to 15 million people across 15 districts. When taken to full scale, the effort is expected to reach 800 million people.

Mapping the road to equity
Many mothers and babies in low-resource settings still suffer and die from preventable causes. To address these inequities, we must first assess them. Where are the gaps? What is working and what is not? PATH investigated the coverage and impact of nine key health interventions across 81 countries. The data gathered will help point the way toward health equity for more mothers and children.

At the AIIMS Hospital human milk bank in New Delhi, India, Pratiksha, a new mother, expresses milk. Anupriya and Varsha, lactation counselors, look on and offer guidance. Pasteurized donor milk offers critical nourishment to newborns.
“We work with stakeholders at every level—engaging directly, building trust, and communicating in terms that relate.”

RAVDEEP GANDHI
Deputy Director of Marketing and Field Operations
Tuberculosis Program
India

A driving force behind the Joint Effort for Elimination of Tuberculosis (JEET), Ravdeep builds vital partnerships with government officials, private providers, and institutions across India. JEET is a nationwide expansion of the Private Provider Interface Agency—PATH’s innovative public-private model for expanding access to tuberculosis treatment.

Bringing better health to market
In close collaboration with country and industry partners, PATH continued expanding access to lifesaving medical oxygen—providing technical assistance to India, Indonesia, Kenya, Malawi, and Senegal; working with the UNICEF Supply Division to support technical specification development and country procurement; and supporting Kenya and Malawi in their efforts to eliminate preventable newborn deaths through the integration of oxygen and pulse oximetry. We also began implementation of the Unitaid-funded Tools for Integrated Management of Childhood Illness project, which aims to identify, test, and improve access to affordable pulse oximeters and multimodal devices that help screen and treat critically ill children in India, Kenya, Myanmar, Senegal, and Tanzania.

Eliminating neglected tropical diseases
In India, PATH supported national and state efforts to eliminate lymphatic filariasis and visceral leishmaniasis, providing technical expertise, standing up data collection and surveillance systems, and streamlining treatment supply chains. In the state of Uttar Pradesh, we reduced the disease burden and case fatalities from acute encephalitis syndrome, a neurological disease that primarily affects children from economically disadvantaged households.

Turning back tuberculosis
PATH improved tuberculosis (TB) services across the entire care cascade by expanding the use of cutting-edge digital technologies. In India, we piloted the use of artificial intelligence to streamline chest X-ray readings, enabling quicker diagnosis and treatment initiation. In Tanzania, we co-developed a mobile phone application that enabled almost 229,900 people to self-screen for TB. In Ukraine, we rolled out use of a smart pill box that reminds patients to take their medication and notifies providers if doses are missed—the approach helped patients achieve 90 percent treatment completion.

Curbing noncommunicable disease
In Vietnam, PATH successfully phased out the Communities for Healthy Hearts project—an innovative health care delivery model that improved hypertension management for hard-to-reach populations—and launched an exciting follow-on project: transforming noncommunicable disease response nationwide by scaling up access to preventive services.

229K people equipped to self-screen for TB with a mobile phone app
2019 financial summary

### Revenue (in thousands)

<table>
<thead>
<tr>
<th>Source</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Foundations</td>
<td>$166,509</td>
</tr>
<tr>
<td>US government</td>
<td>71,817</td>
</tr>
<tr>
<td>Other governments, nongovernmental</td>
<td>46,732</td>
</tr>
<tr>
<td>organizations (NGOs), multilaterals</td>
<td></td>
</tr>
<tr>
<td>Investments</td>
<td>10,379</td>
</tr>
<tr>
<td>Individuals/other</td>
<td>4,632</td>
</tr>
<tr>
<td>Corporations</td>
<td>3,426</td>
</tr>
<tr>
<td><strong>TOTAL REVENUE</strong></td>
<td><strong>$303,495</strong></td>
</tr>
</tbody>
</table>

### Expenses (in thousands)

<table>
<thead>
<tr>
<th>Category</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Program-related:</td>
<td>$254,925</td>
</tr>
<tr>
<td>Global health programs</td>
<td>$95,446</td>
</tr>
<tr>
<td>Essential medicines</td>
<td>47,666</td>
</tr>
<tr>
<td>Technology, analytics, and market innovation</td>
<td>22,383</td>
</tr>
<tr>
<td>Other</td>
<td>5,692</td>
</tr>
<tr>
<td>Program development</td>
<td>2,618</td>
</tr>
<tr>
<td>Subawards to program partners</td>
<td>81,120</td>
</tr>
<tr>
<td><strong>Subtotal program-related</strong></td>
<td><strong>$254,925</strong></td>
</tr>
<tr>
<td>Administrative</td>
<td>36,989</td>
</tr>
<tr>
<td>Fundraising</td>
<td>2,535</td>
</tr>
<tr>
<td><strong>TOTAL EXPENSES</strong></td>
<td><strong>$294,449</strong></td>
</tr>
</tbody>
</table>

### Assets (in thousands)

<table>
<thead>
<tr>
<th>Source</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash and cash equivalents</td>
<td>$26,554</td>
</tr>
<tr>
<td>Invested grant funds</td>
<td>177,558</td>
</tr>
<tr>
<td>Contributions and awards receivable</td>
<td>43,347</td>
</tr>
<tr>
<td>Other</td>
<td>17,541</td>
</tr>
<tr>
<td><strong>TOTAL ASSETS</strong></td>
<td><strong>$265,000</strong></td>
</tr>
</tbody>
</table>

### Liabilities and net assets (in thousands)

<table>
<thead>
<tr>
<th>Source</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total liabilities</td>
<td>$223,056</td>
</tr>
<tr>
<td>Net assets:</td>
<td></td>
</tr>
<tr>
<td>Without donor restrictions</td>
<td>$21,320</td>
</tr>
<tr>
<td>With donor restrictions</td>
<td>20,624</td>
</tr>
<tr>
<td><strong>Total net assets</strong></td>
<td><strong>$41,944</strong></td>
</tr>
<tr>
<td><strong>TOTAL LIABILITIES AND NET ASSETS</strong></td>
<td><strong>$265,000</strong></td>
</tr>
</tbody>
</table>

---

**Clinical trial monitoring**

PATH is committed to ensuring that the clinical trials we sponsor, fund, or otherwise support are registered in a publicly available clinical trial registry, in accordance with international standards established by the World Health Organization. PATH reports progress toward this commitment annually. Monitoring results as of November 1, 2019, are summarized as follows:

- Of the 40 clinical trials initiated on or after September 1, 2016 (when PATH’s policy took effect), all were registered in a WHO Network primary registry.
- 13 of the 40 clinical trials were 12 months past primary study completion, of which:
  - 9 had summary results submitted to a trial registry; and
  - 4 had yet to have summary results submitted.
- 5 of the 40 clinical trials were 24 months past study completion, of which:
  - 4 had manuscripts submitted for peer-reviewed journal publication; and
  - 1 had yet to have a manuscript submitted.

**Reducing the cost of cleaning**

PATH is continuing to advance the introduction of electrochlorinators into health systems in Ghana, Mozambique, and Uganda. This simple device—which produces chlorine from salt, water, and electricity—plays a critical role in system strengthening by expanding access to an essential, low-cost disinfectant. In 2019, we completed a validation study of 40 on-site electrochlorinator prototype units in 24 health facilities.

**Expanding access to contraception**

In 2019, the DMPA-SC Access Collaborative facilitated contraceptive introduction in seven countries, providing technical assistance, scale-up planning, and implementation support for a range of contraceptive options. The collaborative also facilitated participation across countries by exchanging information, results, and lessons learned; troubleshooting challenges; and accelerating the adoption of best practices.

---

**Notes:** The above financial summary is based on PATH’s audited financial statements, which are audited by the firm Clark Nuber P.S. Full copies are available on our website at [www.path.org](http://www.path.org). PATH is an international, nonprofit, nongovernmental organization. Our mission is to advance health equity through innovation and partnerships. Contributions to PATH are tax-exempt under US IRS code 501(c)(3).
The following list of supporters includes those who gave $1,000 or more in funding to PATH through grants, donations, and in-kind contributions in 2019. We are deeply grateful to you all—for your generous investment and collaboration, for your commitment to improving public health, and for sharing the journey to health equity.

Interested in joining our global team? Become a supporter today.

Foundations
Anonymous (4)
All The Sky Foundation
Bainum Family Foundation
Bill & Melinda Gates Foundation
Charities Aid Foundation of the UK
Conrad N. Hilton Foundation
David and Lucile Packard Foundation
Donald A. Pels Charitable Trust
The Elsie P. van Buren Foundation
Family Larson-Rosenquist Foundation
Fidelity Charitable Gift Fund
Fondation Botnar
Fred R. Smith Foundation
The Global Good Fund
Greater Washington Community Foundation
Hilton Prize Coalition
The Horace W. Goldsmith Foundation
The Hudson Bay Way Foundation
ImpactAssets, Inc.
The Kaphan Foundation
Kitsap Community Foundation
Leslie Fund, Inc.
Lyda Hill Foundation
Manulife Family Foundation
Martens Bash Foundation
Martin-Fabert Foundation
Merrill Schneider Foundation
M.J. Murdoch Charitable Trust
MMS Giving Foundation
Moccasin Lake Foundation
Morgan Stanley Global Impact Funding Trust
The Nararo Foundation
Norcliffe Foundation
Open Road Alliance
Patrick J. McGovern Foundation
RIGHT Fund
The Rockefeller Foundation
Schwab Charitable Fund
The Seattle Foundation
Shickman Family Foundation
Silicon Valley Community Foundation
Starfish Foundation
The Turnip Top Foundation
United Jewish Foundation
United Way of Snohomish County
Vanguard Charitable Endowment
William and Flora Hewlett Foundation
The Wilson Family Foundation

Governments and international agencies
Coalition for Epidemic Preparedness Innovations
European Commission
Federal Ministry for Economic Cooperation and Development, Germany
Gavi, the Vaccine Alliance
The Global Fund to Fight AIDS, Tuberculosis and Malaria

Nongovernmental and health organizations and universities
BEMPU Health
Global Impact
HarvestPlus
The Nature Conservancy
NCD Alliance
Pacific Northwest Enterprise Risk Forum

Corporations and corporate foundations
Anonymous (2)
Abbot Laboratories
Aetna Inc.
Alteryx
Amazon
AmazonSmile Foundation
Ameriprise Financial Services, Inc.
Amica Companies Foundation
ARM Company
AstraZeneca
Bank of America Charitable Gift Fund
Bayer Pharma AG
Beijing Institute of Biological Products Co., Ltd.
Box, Inc.
CBRE
Clark Nuber P.S.
Davis Wright Tremaine LLP
EMI Investment Group LLC
Exasol
ExxonMobil Foundation
Facebook
GLY Construction, Inc.
Goldman Sachs Philanthropy Fund
Google Inc.
Huntington Steele LLC
Inovio Pharmaceuticals
International Federation of Pharmaceutical Manufacturers Association
Johnson & Johnson
Kaiser Permanente Washington
Kessel Medintim GmbH
Lanzhou Institute of Biological Products Co., Ltd.
Mapbox
Merck & Company, Inc.
Merrill Lynch
Microsoft Corporation
Mott MacDonald Limited

NBBJ LP
Novartis Foundation
Novo Nordisk A/S
PayPal Giving Fund
Pfizer Foundation
Pfizer, Inc.
Philly
Rapid Learning Cycles Institute
Schoenfeld Interiors
Shell Oil Matching Gifts
Siemens Foundation
Tableau Foundation
Tableau Software, Inc.
Temptime Corporation
TOMS Shoes
UBS Wealth Management
The Walt Disney Company Foundation

Individuals
$100,000+
Anonymous (1)
Dean & Vicki Allen/McKinstry Charitable Foundation
Mike and Nelly Silly-Arougheti
The Laurence and Michele Chang Foundation
Steve Davis and Bob Evans de Jonge Family
Beth Galetti and Jeff Vanlaningham
Dennis and Jane Henner
Dr. Vaughn Himes and Marie Ann Bohn
Joel & Michelle Holsinger Foundation
Katherine and David De Bruyn
Jacinta Fitzgerald
Andrew Frey
Mike Gailgorn
Gene and Mary Kay Gardner
William Gates and Mimi Gates
Kathy Gleason
Adrian Graham
Chris Honick and Thy Tran
Jessica Hu and Jonathan Eddy
Mary Ellen and Pat Hughes
Bruce and Cris Jaffe
Howard and Nancy Johnson
Patricia Keegan and Tom Lennon
David and Cynthia King
Sarah and Mark Kranwinkle
Lutz Latta
James Mason and Danna Klein
Brian McAndrews and Elise Hollschu
Susan Miller and Kenneth Kendler
Sandia J. Moss
John and Megan Pigott
Catherine and Thurston Roach
John and Nancy Rudolf
Benjamin Segal and Jacqueline Mahal
Sameer and Nida Shikalgar
Brad and Danielle Tilden
Dilip Wagle and Darshana Shanbhag

$10,000–$99,999
Anonymous (7)
Tom Alberg and Judi Beck
Ric and Kaylene Anderson
Phyllis and Bill Campbell
Kelly and Michael Chang
Ram and Prasnana Cherila
Lisa and Tom Cohen
Lowell Cook
Kathleen and Christopher Davis
Katherine and David De Bruyn
Stephanie Evans
Jacintha Fitzgerald
Andrew Frey
Mike Gailgorn
Gene and Mary Kay Gardner
William Gates and Mimi Gates
Kathy Gleason
Adrian Graham
Chris Honick and Thy Tran
Jessica Hu and Jonathan Eddy
Mary Ellen and Pat Hughes
Bruce and Cris Jaffe
Howard and Nancy Johnson
Patricia Keegan and Tom Lennon
David and Cynthia King
Sarah and Mark Kranwinkle
Lutz Latta
James Mason and Danna Klein
Brian McAndrews and Elise Hollschu
Susan Miller and Kenneth Kendler
Sandia J. Moss
John and Megan Pigott
Catherine and Thurston Roach
John and Nancy Rudolf
Benjamin Segal and Jacqueline Mahal
Sameer and Nida Shikalgar
Brad and Danielle Tilden
Dilip Wagle and Darshana Shanbhag
Mrs. Y. P. Chan and Melanie Hayden
Taras Bobrovytsky
Victoria Buker
Anne Bingham
Andy and Teryn Bench
Anonymous (49)
John Bukowsky
Jonathan and Bobbe Bridge
John Bates and Carolyn Corvi
Jillian Barron and Jonas Simons
Peter Bladin and Donna Lou
Steve Bolliger and Candace Smith
Marcy Bordeax
Catherine Bourdeau
Cara and Thomas Bradley
Branson Family Foundation
Jonathan and Bobbe Bridge
Margarid Brittton
Louise and Andrew Bronstein
Victoria Baker
John Bukowsky
Ramona Brykit
Barbara and Michael Cabay
David and Heidi Capelli
Stephen Carr
Y.P. Chan and Melanie Hayden
Brian and Allayne Chappelle
Dr. Molly Joel Coye
Judy Cromett
Dr. Brenda Crowe and Jan Erik Backlund
Peter and Elizabeth Dahlberg
Vijay Daniel
Barbara and Ted Daniels
Gordon Davidson
Gordon and Katherine Day
Aury Deilmar and Melissa Felix
Loren and Sara Den Herder
Frank Denman
Karen and Jeff DeToro
Barbara Dingfield
Emily Ditty
Dr. Roscilius N. Doan and Dr. Virginia Warfield
Lisa and Bob Donegan
Emer Dooley and Rob Short
Barton and Andrea Duncan
Ken Duncan and Tanya Parish
Jenny Durkan
Joseph and Kay Dusek
Nancy and Bernard Ebert
Kathleen and George Edwards
Megin and Derek Edwards
Kay Egawa
Nancy Ericsson
Niels and Denise Ferguson
Scott Finfrock
Alison Fitch
Manny Fitzgerald
Brenda and Adam Flynn
Bert and Candace Forbes
Susan Fraser
Katharyn Gerlich
John Giglio and Susan Winckler
Dr. and Mrs. Allen M. Gown
Laura Grady Hart
Robert Green
Patrick Griffin and Lauren Cadish
Sean L. Guichon
Alisa Gutierriz-Vitello
Robert and Elke Hagge
Regina Hall
Nick and Leslie Hanauer
Dr. F. Ann Hayes
David Heckerman
Clair Hector and Paul Garner
Rodger Heggen
Denis Heidenreich and Francis Proctor
Chris and Victoria Helm
Corinne and Jason Henderson
Robert Henry and Lee Foote
Jan Hesness
Kathy Hettick
Linda and Robert Hildreth
RJ Hilgers
Dean and Shirley Hobson
Eric Hooper and Kristie Gibney
Toni Hooper and Alfred Nettles
Kathleen Irwin
Glenn Ishioka
Stella Jacobs*
The James Family Foundation
Joshua, Elin
Sally and Warren Jewell
David Johnson
Greg Johnson
Barb and Chris Jones
Nader Kabbani
Dana Karash
David Kaslow
Robert and Sandra Khan
Gary and Marilyn Kneepkens
Anne and Michael Kripick
Sanjiv Kumar and Manosora Rashid
Sally Lake
David Landau and Tanya Brunner
Daniel Laster
Lyn Sullivan Lee and Doug Lee
James Leslie and Jeanne Tweten
Vicki Leslie and Richard Weening
Terry Lin
Gary Locke
Julie and Tom Lombardo
Scott and Darinee Louvau
Jan- Willem Maessen and Andrea Humez Maessen
Richard and Dianna Mahoney
Judsen Marquardt and Connie Niva
Masterson/Blevins
Mayer-Nye Charitable Fund
Keith & Mary Kay McCaw
Family Foundation
Erinn McIntyre and John Wechkin
Bruce McKinney
Bruce McNamer
Dr. Sandy Mezler and Ellen Evans
David and Marianne Mersereau
Lawrence and Bernie Meurk
Mary Miller
David C. Montgomery
Anthony Moore and Kristiana Lee
Sally Musseter
Joseph Mutale
Scott and Erica Myers
Neal, Paul, and Max Myrick-Teske
Beth Nelson
Robin O'Brien and Frank Kuykendall
Kathy O'Riscoll
John and Mary Pat Osterhaus
Robert Osterhaus
Alan Parrish
Norma Pawley and Jason Gans
Dr. and Mrs. Gordon W. Perkin
Van Perry
Louise Pietrafesa
Christopher Pratley and Seiko Kobayashi
Katherine Radeka
Chip Ragen
Praveen Raja
Susan Ranney and Lee Edlefsen
John Henri Richardson
Christoph Richey
Michael Rollinger and Sarah Ames
Elizabeth Romney and Jim Giles
Timothy and Lori Rowe
Evelyne Rozer and Matt Griffin
H. Jon and Judith Runstad
Carole Rush and Richard Andler
Jeff Sakuma and Ron Pederson
Helen Samuels
Larry and Kelly Sanderson
Jean and Jack Sargent
Kammerer Schneider and Gregory Eberle
Amy Scott and Stephen Alley
Jonathan and Xixi Shakes
Alefshy Shambhooa and Vilas Rao
Dan Shapiro
Keith and Michelle Sink
Christina M. Spadoni
Krish Srinivasan
Jen Steele
David and Ashley Steinke
Elizabeth Strickland
Cynthia Stroum
Hosanna Swanner
Daniel D. Syndal
Edward and Victoria Tackenberg
Brian and Karen Tallesin
Theresa Tamura
Thor and Donna Thorson
Alex and Alicia Thrasher
Christopher Tompkins and Mary Winslow
DaveTrigger
Rajendra Unni
John Vadino and Mary Kay Bisignano-Vadino
George Vanderheiden
Stephanie Van Eyk
Nicholas Vavra
Ben and Preeti Verghese
Mary Wagner
Maggie Walker
Joseph Wallin and Andrea Begel
Steve Warkany

Ruth and Todd Warren
Helena Wayth
David and Marsha Weil
Elon Weiss
The Wells/Burdick Family
Whatley Family Foundation
Turi Widsteen and Keith White
Carol Wolf
H.S. Wright III and Katherine Janeway
Chien-Fu Jeff Wu
Craig Zajac
Judith Zeh
Margot Zimmerman
PATH Futures (Legacy Society)
Anonymous (4)
Ann E. Brudno and Kenneth L. Routh
Roy and Carolyn Chapel
Sharon Cooper and Dan Koebel
Lance Eisenberg
Lee D. Hwang
Janet Aldrich Jacobs and Bernie L. Jacobs, Jr.
Marlene and Howard Koons
Nancy and Gary Lande
George Lindquist
James J. and Kathleen Lippard
Amy MacIver
Matt Meko
John and Irene Meulemans
Paul Moore
Peggy Morrow
Erick and Marta Rabins
Dr. Susan Safer
Patrick and Karen Scott
Michael Sullivan
Anne von Rosenstiel*

*deceased
“My time at PATH has been one of my life’s great privileges. I am proud to leave behind an organization committed to challenging old assumptions and pushing tirelessly for health equity.”

STEVE DAVIS
Former President and CEO
PATH

Under Steve’s leadership, PATH improved health for hundreds of millions of people; developed and/or introduced a wave of innovative products, including new vaccines, drugs, diagnostics, devices, and digital tools; created centers of excellence in vaccines, malaria, digital health, and primary health care; and united the organization under a single, globally recognized brand.

Thank you, Steve, for your passion, for your leadership, and for moving humanity forward.